Patient No.
|
ECOG PS
|
Histological subtype
|
Stage
|
Primary site
|
Metastatic site
|
Previous lines of chemotherapy
|
Response
|
PFS (Months)
|
---|
1
|
1
|
UPS
|
IV
|
Head
|
Lung and bone
|
1
|
PR
|
5
|
2
|
1
|
UPS
|
IV
|
Extremities
|
Lung and lymph nodes
|
1
|
PR
|
3.5
|
3
|
0
|
UPS
|
IV
|
Extremities
|
Lung and bone
|
2
|
SD
|
3
|
4
|
0
|
UPS
|
IV
|
Neck
|
Bone
|
2
|
SD
|
2.5
|
5
|
0
|
UPS
|
IV
|
Extremities
|
Lung
|
2
|
PD
|
2
|
6
|
0
|
UPS
|
IV
|
Extremities
|
Bone
|
2
|
PD
|
1.8
|
7
|
1
|
UPS
|
IV
|
Extremities
|
Lung
|
1
|
PD
|
1
|
8
|
1
|
Angiosarcoma
|
IV
|
Head
|
Liver
|
2
|
CR
|
15
|
9
|
0
|
Angiosarcoma
|
IV
|
Trunk
|
Bone
|
2
|
PR
|
7.8
|
10
|
1
|
Angiosarcoma
|
IV
|
Extremities
|
Lung
|
2
|
PR
|
4
|
11
|
0
|
Angiosarcoma
|
IV
|
Extremities
|
Lung
|
2
|
SD
|
4.5
|
12
|
0
|
Angiosarcoma
|
IV
|
Trunk
|
Lung
|
2
|
PD
|
2
|
13
|
1
|
Epithelioid sarcoma
|
IV
|
Extremities
|
Lung
|
2
|
PR
|
2.8
|
14
|
1
|
Epithelioid sarcoma
|
IV
|
Trunk
|
Lung and lymph nodes
|
2
|
SD
|
3
|
15
|
1
|
Epithelioid sarcoma
|
IV
|
Trunk
|
Lung
|
2
|
SD
|
2.8
|
16
|
0
|
Epithelioid sarcoma
|
IV
|
Extremities
|
Lung
|
1
|
PD
|
1.8
|
17
|
1
|
Epithelioid sarcoma
|
IV
|
Extremities
|
Lung and bone
|
2
|
PD
|
1.3
|
18
|
1
|
Fibrosarcoma
|
IV
|
Trunk
|
Lung
|
2
|
PR
|
4.3
|
19
|
1
|
Fibrosarcoma
|
IV
|
Extremities
|
Lung
|
2
|
SD
|
2.5
|
20
|
0
|
Fibrosarcoma
|
IV
|
Extremities
|
Lung
|
1
|
PD
|
1.5
|
21
|
0
|
Fibrosarcoma
|
IV
|
Extremities
|
Liver
|
3
|
PD
|
1.3
|
22
|
0
|
Synovial sarcoma
|
IV
|
Neck
|
Lung
|
2
|
PD
|
1.8
|
23
|
0
|
Synovial sarcoma
|
IV
|
Extremities
|
Lung
|
2
|
PD
|
1.5
|
24
|
1
|
Synovial sarcoma
|
IV
|
Trunk
|
Lung
|
3
|
PD
|
1.5
|
25
|
0
|
Leiomyosarcoma
|
IV
|
Extremities
|
Lung
|
2
|
SD
|
2.8
|
26
|
1
|
Leiomyosarcoma
|
IV
|
Trunk
|
Liver
|
1
|
PD
|
1.3
|
27
|
0
|
Pleomorphic liposarcoma
|
IV
|
Extremities
|
Lung
|
2
|
PD
|
1.8
|
28
|
1
|
Rhabdomyosarcoma
|
IV
|
Head
|
Lung
|
1
|
PD
|
1.5
|
- The clinical and pathologic stages are expressed according to the American Joint Committee on Cancer (8th Edition) TNM staging. Tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1), and were categorized as CR Complete response, PR Partial response, SD Stable disease, or PD Progressive disease. PFS Progression-free survival was calculated from the date of the first nab-paclitaxel plus PD-1 inhibitor treatment until the date of documented progression
- Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, UPS Undifferentiated pleomorphic sarcoma